Holen Sie sich die Stockscreener-App
3.025
6.64%
0.185
Schlusskurs vom Vortag:
$2.84
Offen:
$2.87
24-Stunden-Volumen:
3.06M
Relative Volume:
1.00
Marktkapitalisierung:
$385.87M
Einnahmen:
$4.21M
Nettoeinkommen (Verlust:
$-97.67M
KGV:
-3.2527
EPS:
-0.93
Netto-Cashflow:
$-70.76M
1W Leistung:
+14.29%
1M Leistung:
+14.29%
6M Leistung:
-2.62%
1J Leistung:
-30.70%
1-Tages-Spanne:
$2.86
$3.07
1-Wochen-Bereich:
$2.635
$3.07
52-Wochen-Spanne:
$2.01
$6.33
Absci Corp Stock (ABSI) Company Profile
Firmenname
Absci Corp
Sektor
Branche
Telefon
(360) 949-1041
Adresse
18105 SE MILL PLAIN BLVD, VANCOUVER
Vergleichen Sie ABSI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
3.025 | 349.51M | 4.21M | -97.67M | -70.76M | -0.93 |
|
ONC
Beone Medicines Ltd Adr
|
255.53 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.75 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
492.83 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-22 | Eingeleitet | Needham | Buy |
| 2024-10-02 | Eingeleitet | Guggenheim | Buy |
| 2024-07-03 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-07-18 | Eingeleitet | Truist | Buy |
| 2022-03-02 | Fortgesetzt | Cowen | Market Perform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-11-10 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-08-16 | Eingeleitet | BofA Securities | Neutral |
| 2021-08-16 | Eingeleitet | Cowen | Market Perform |
| 2021-08-16 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-16 | Eingeleitet | Stifel | Hold |
Alle ansehen
Absci Corp Aktie (ABSI) Neueste Nachrichten
Two Sigma Investments LP Raises Stock Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Deutsche Bank AG Purchases 28,073 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
Absci (NASDAQ:ABSI) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Top 5 AI & Digital Biotech Companies (June 2025) - Securities.io
Absci (NASDAQ:ABSI) Stock Rating Lowered by Wall Street Zen - Defense World
AbSci Corp (ABSI) Sees Borrow Rate Increase | ABSI Stock News - GuruFocus
Woodline Partners LP Decreases Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Northern Trust Corp Has $1.72 Million Stock Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Brokerages Set Absci Co. (NASDAQ:ABSI) Price Target at $8.40 - MarketBeat
Wall Street Zen Upgrades Absci (NASDAQ:ABSI) to Hold - Defense World
Ameriprise Financial Inc. Sells 23,668 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
AbSci Corp (ABSI): Key Indicator Shows Noticeable Increase | ABSI Stock News - GuruFocus
Catherine Wood's Strategic Acquisition of Absci Corp Shares - GuruFocus
Schonfeld Strategic Advisors LLC Has $144,000 Stake in Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci to Participate in Upcoming Investor Conferences - GlobeNewswire
Absci Sets Stage for Major AI Breakthroughs at Goldman Sachs and Jefferies Healthcare Conferences - Stock Titan
Needham & Company LLC Reiterates Buy Rating for Absci (NASDAQ:ABSI) - MarketBeat
Price T Rowe Associates Inc. MD Increases Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Absci Co. (NASDAQ:ABSI) Shares Sold by Stifel Financial Corp - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Absci (NASDAQ:ABSI) - Defense World
Absci Corp’s Earnings Call: A Promising Outlook - TipRanks
Absci Corporation (NASDAQ:ABSI) Q1 2025 Earnings Call Transcript - Insider Monkey
Absci First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Dimensional Fund Advisors LP Acquires 241,779 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
ABSI: Needham Reiterates Buy Rating and $9 Price Target | ABSI Stock News - GuruFocus
Absci (ABSI) Initiates Phase 1 Study of AI-Designed Antibody ABS-101 | ABSI Stock News - GuruFocus
Absci (ABSI) Launches First Human Trial for ABS-101 - GuruFocus
ABSI: Needham Reiterates Buy Rating and $9 Price Target | ABSI S - GuruFocus
Assessing Absci: Insights From 6 Financial Analysts - Benzinga
Absci Corporation Advances Clinical Programs with Strong Q1 Results - TipRanks
Fred Alger Management LLC Reduces Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci Corp Q1 2025 Earnings: EPS Beats Estimates at -$0.21, Reve - GuruFocus
Absci earnings beat by $0.01, revenue fell short of estimates - Investing.com
Earnings call transcript: Absci Q1 2025 sees stock surge post-earnings By Investing.com - Investing.com Nigeria
AbSci (ABSI) Anticipates Significant Post-Earnings Movement | AB - GuruFocus
Earnings call transcript: Absci Q1 2025 sees stock surge post-earnings - Investing.com
Absci Q1 2025 Earnings Call Transcript - MarketBeat
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Absci Corp reports results for the quarter ended March 31Earnings Summary - TradingView
ABSI Surprises with Q1 Revenue Beat and Expands Clinical Initiat - GuruFocus
ABSI Surprises with Q1 Revenue Beat and Expands Clinical Initiatives | ABSI Stock News - GuruFocus
Absci reports first participants dosed in Phase 1 ABS-101 trial - TipRanks
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results - GlobeNewswire
Absci Announces First Participants Dosed In Phase 1 Clinical Trial Of Abs-101, A Potential Best-In-Class Anti-TL1a Antibody For The Treatment Of Inflammatory Bowel Disease - marketscreener.com
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease - GlobeNewswire
Breakthrough: First-Ever AI-Designed IBD Treatment Begins Human Trials with Quarterly Dosing Potential - Stock Titan
What To Expect From Absci Corp (ABSI) Q1 2025 Earnings - GuruFocus
Wells Fargo & Company MN Has $115,000 Stock Position in Absci Co. (NASDAQ:ABSI) - Defense World
Absci (ABSI) Projected to Post Quarterly Earnings on Tuesday - Defense World
Absci (ABSI) Expected to Announce Earnings on Tuesday - MarketBeat
Mariner LLC Purchases New Stake in Absci Co. (NASDAQ:ABSI) - Defense World
Finanzdaten der Absci Corp-Aktie (ABSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Absci Corp-Aktie (ABSI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Jonasson Zachariah | CFO / CBO |
Jun 13 '24 |
Sale |
4.98 |
19,859 |
98,892 |
384,751 |
1.30%
3.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):